Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia

NCT04174599 is registered in ClinicalTrials.gov with EVIVE Biotechnology as lead sponsor.

NCT NCT04174599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04174599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
Lead sponsor
EVIVE Biotechnology
Phase
Phase 3
Overall status
Completed
Start date
April 12, 2018
Completion date
June 19, 2019
Enrollment
242 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neutropenia